BioAtla, Inc. (BCAB)


-0.20 (-5.08%)
Symbol BCAB
Price $3.74
Beta 0.000
Volume Avg. 0.52M
Market Cap 139.928M
Shares () -
52 Week Range 2.01-43.61
1y Target Est -
DCF Unlevered BCAB DCF ->
DCF Levered BCAB LDCF ->
ROE -37.86% Strong Sell
ROA -31.79% Strong Sell
Operating Margin -
Debt / Equity 21.36% Neutral
P/E -
P/B 0.73 Buy


Consensus EPS

Upgrades & Downgrades

Latest BCAB news

Dr. Jay M. Short
NASDAQ Global Market

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.